Voting Common Stock, par value $0.0001 per share

MAPLIGHT THERAPEUTICS, INC.

800 Chesapeake Drive, Redwood City, CA, 94063

Novo Holdings A/S beneficially owns 2,086,622 shares of common stock representing approximately 4.9% of the Issuer's outstanding shares of common stock (the "Novo Shares"), based upon 42,618,165 shares of common stock outstanding as of May 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 14, 2026.

Novo Holdings A/S is a Danish corporation wholly owned by the Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

Except as set forth below, Novo Holdings A/S has not effected any transactions with respect to the Issuer's common stock during the past sixty days and neither the Foundation nor any person listed on Schedule I has effected any transactions in the Issuer's Common Stock within the past 60 days. On July 30, 2026, Novo Holdings A/S sold the following shares in open market transactions: - 1,314,195 shares of common stock in a single transaction at a price of $12.00 per share; - 220,723 shares of common stock at prices ranging from $13.55 to $14.54 per share (a weighted-average price of $14.19 per share); and - 65,082 shares of common stock at prices ranging from $14.55 to $15.00 per share (a weighted-average price of $14.69 per share).

Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.

The Reporting Persons ceased to be the beneficial owners of more than five percent of the common stock on July 30, 2026.